Top

Reactions Weekly

Published in:

01-04-2024 | Ruxolitinib | Case report

Ruxolitinib

Lack of efficacy

Published in: Reactions Weekly | Issue 1/2024

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Cheng Q, et al. Efficacy and Safety in Early application of Ruxolinitib for high-risk: Acute lymphoblastic leukemia to prevent GVHD and recurrence after allogeneic hematopoietic stem cell transplantation. Transplant Immunology 83: Jan 2024. Available from: URL: https://dx.doi.org/10.1016/j.trim.2023.101978 [Summarised from an abstract]

Title: Ruxolitinib
Lack of efficacy
Publication date: 01-04-2024
Publisher: Springer International Publishing
Keywords: Ruxolitinib
Graft-Versus-Host Disease
Graft-Versus-Host Disease
Acute Lymphoblastic Leukemia
Stem Cell Transplantation
Stem Cell Transplantion
Stem Cell Transplantation
Published in: Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-024-55796-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Ruxolitinib

Lack of efficacy

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2024

COVID-19-vaccine

Mepolizumab

Fluoxetine

Antineoplastics/plasma

Ibuprofen

COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology